Lupin launches generic Nystatin and Triamcinolone Acetonide Cream USP 100,000 units/gm; 0.1%

Pharma major Lupin announced the launch of Nystatin and Triamcinolone Acetonide Cream USP 100,000 units/gm; 0.1 %, having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin's Nystatin and Triamcinolone Acetonide Cream USP 100,000 units/gm; 0.1 % is the generic equivalent of Taro Pharmaceuticals' Nystatin and Triamcinolone Acetonide Cream. It is indicated for the treatment of cutaneous candidiasis.

Nystatin and Triamcinolone Acetonide Cream had annual sales of $54.3 million in the US (IQVIA MAT September 2018).

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 13^th largest generics pharmaceutical company in terms of market capitalization (30^th September 2018, Bloomberg) and the 8^th largest generics pharmaceutical company in terms of revenues (30^th June 2018, Bloomberg LTM) globally. The Company is the 3^rd largest pharmaceutical player in the US by prescriptions for the Total Market (IQVIA MAT September 2018); 3^rd largest Indian pharmaceutical company by global revenues (30^th June 2018, Bloomberg LTM); 6^thlargest generic pharmaceutical player in Japan (IQVIA MAT September 2018) and 5^thlargest company in the Indian Pharmaceutical Market (IQVIA MAT September 2018).

For the financial year ended 31^st March, 2018, Lupin's Consolidated sales and Net profits before exceptional items were at Rs. 155,598 million (USD 2.41 billion) and Rs. 13,934 million (USD 216 million) respectively.